| 000 | 01787 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517181659.0 | ||
| 264 | 0 | _c20190916 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1555-905X | ||
| 024 | 7 |
_a10.2215/CJN.04650417 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTong, Lili | |
| 245 | 0 | 0 |
_aDiabetic Kidney Disease. _h[electronic resource] |
| 260 |
_bClinical journal of the American Society of Nephrology : CJASN _c02 2018 |
||
| 300 |
_a335-338 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Conference; Journal Article | ||
| 650 | 0 | 4 |
_aAngiotensin Receptor Antagonists _xadverse effects |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aBiopsy |
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 | _aDecision Support Techniques |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xdiagnosis |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDiuretics _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlomerular Filtration Rate _xdrug effects |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xetiology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 |
_aRenin-Angiotensin System _xdrug effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAdler, Sharon G | |
| 773 | 0 |
_tClinical journal of the American Society of Nephrology : CJASN _gvol. 13 _gno. 2 _gp. 335-338 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2215/CJN.04650417 _zAvailable from publisher's website |
| 999 |
_c27698789 _d27698789 |
||